Clinical Trial Update: Stereotactic Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) for Oligometastatic Renal Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial assessing stereotactic radiotherapy with pembrolizumab for oligometastatic renal cell carcinoma has completed with results posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Peter MacCallum Cancer Centre, Australia | Conditions: Renal Cell Carcinoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-03